HUP0302553A2 - Egy izotiazol-4-karbonsavamid sói és eljárás az előállításukra és ezek alkalmazására a túlzott mértékű sejtburjánzás visszaszorítására alkalmas gyógyszerkészítmények előállítására - Google Patents

Egy izotiazol-4-karbonsavamid sói és eljárás az előállításukra és ezek alkalmazására a túlzott mértékű sejtburjánzás visszaszorítására alkalmas gyógyszerkészítmények előállítására

Info

Publication number
HUP0302553A2
HUP0302553A2 HU0302553A HUP0302553A HUP0302553A2 HU P0302553 A2 HUP0302553 A2 HU P0302553A2 HU 0302553 A HU0302553 A HU 0302553A HU P0302553 A HUP0302553 A HU P0302553A HU P0302553 A2 HUP0302553 A2 HU P0302553A2
Authority
HU
Hungary
Prior art keywords
preparation
isothiazole
carboxamide
salts
ureido
Prior art date
Application number
HU0302553A
Other languages
English (en)
Inventor
Thomas G. Gant
Glenn Robert Williams
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0302553A2 publication Critical patent/HUP0302553A2/hu
Publication of HUP0302553A3 publication Critical patent/HUP0302553A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Az (I) képletű 3-(4-bróm-2,6-difluor-benziloxi)-5-[3-(4-pirrolidin-1-il-butil)-ureido]-izotiazol-4-karbonsavamid hidroklorid, hidrobromid,hemicitrát, acetát, p-toluolszulfonát, L-tartarát, hemiszukcinát ésmetánszulfonát só formái, az ezeket vagy szolvátjaikat tartalmazógyógyászati készítmények, továbbá eljárás az említett vegyületekfelhasználására gyógyászati készítmények előállításánál, valaminteljárás a 3-(4-bróm-2,6-difluor-benziloxi)-5-[3-(4-pirrolidin-1-il-butil)-ureido]-izotiazol-4-karbonsavamid hidrobromid és hemicitrát sóformái előállítására. Ó
HU0302553A 2000-11-28 2001-11-19 Salts of a isothiazole-4-carboxamide and process for their preparation and use for the preparation of anti-hyperproliferation agents HUP0302553A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25351300P 2000-11-28 2000-11-28
PCT/IB2001/002193 WO2002044158A1 (en) 2000-11-28 2001-11-19 Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents

Publications (2)

Publication Number Publication Date
HUP0302553A2 true HUP0302553A2 (hu) 2003-11-28
HUP0302553A3 HUP0302553A3 (en) 2009-03-30

Family

ID=22960587

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302553A HUP0302553A3 (en) 2000-11-28 2001-11-19 Salts of a isothiazole-4-carboxamide and process for their preparation and use for the preparation of anti-hyperproliferation agents

Country Status (50)

Country Link
US (1) US6831091B2 (hu)
EP (1) EP1337521B1 (hu)
JP (2) JP2004514714A (hu)
KR (2) KR20050116401A (hu)
CN (1) CN1231474C (hu)
AP (1) AP2001002358A0 (hu)
AR (1) AR031512A1 (hu)
AT (1) ATE340786T1 (hu)
AU (2) AU1420402A (hu)
BG (1) BG107752A (hu)
BR (1) BR0115621A (hu)
CA (1) CA2430065C (hu)
CR (1) CR6963A (hu)
CY (1) CY1106240T1 (hu)
CZ (1) CZ20031315A3 (hu)
DE (1) DE60123461T2 (hu)
DK (1) DK1337521T3 (hu)
DO (1) DOP2001000288A (hu)
EA (1) EA005859B1 (hu)
EC (1) ECSP034628A (hu)
EE (1) EE200300247A (hu)
ES (1) ES2271086T3 (hu)
GE (1) GEP20053652B (hu)
GT (1) GT200100237A (hu)
HK (1) HK1059085A1 (hu)
HN (1) HN2001000268A (hu)
HR (1) HRP20030408A2 (hu)
HU (1) HUP0302553A3 (hu)
IL (1) IL155371A0 (hu)
IS (1) IS6788A (hu)
MA (1) MA26960A1 (hu)
MX (1) MXPA03004714A (hu)
MY (1) MY136686A (hu)
NO (1) NO325187B1 (hu)
NZ (1) NZ525788A (hu)
OA (1) OA12532A (hu)
PA (1) PA8533801A1 (hu)
PE (1) PE20020591A1 (hu)
PL (1) PL362079A1 (hu)
PT (1) PT1337521E (hu)
SI (1) SI1337521T1 (hu)
SK (1) SK5862003A3 (hu)
SV (1) SV2002000748A (hu)
TN (1) TNSN01167A1 (hu)
TW (1) TWI287542B (hu)
UA (1) UA74221C2 (hu)
UY (1) UY27039A1 (hu)
WO (1) WO2002044158A1 (hu)
YU (1) YU36403A (hu)
ZA (1) ZA200303341B (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
JP4511352B2 (ja) * 2002-07-25 2010-07-28 ファイザー・インク 抗癌薬として有用なイソチアゾール誘導体
GEP20074134B (en) * 2002-08-19 2007-06-25 Pfizer Prod Inc Combination therapy for hyperproliferative diseases
CA2526636C (en) 2003-05-20 2012-10-02 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr
CL2004001834A1 (es) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
NZ546447A (en) * 2003-10-27 2009-02-28 Merck & Co Inc ((1R,3S)-3-isopropyl-3-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-methoxytetrahydro-2H-pyran-4-yl]amine succinate
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
WO2005102327A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Dosage forms and methods of treatment using vegfr inhibitors
MXPA06012394A (es) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
TW200538104A (en) * 2004-05-17 2005-12-01 Pfizer Prod Inc Phenyl derivatives for the treatment of abnormal cell growth
JP2008510734A (ja) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
BR122020011899B1 (pt) 2006-06-16 2021-05-11 H. Lundbeck A/S processos para a preparação de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazina e para a fabricação do sal de adição de ácido bromídrico correspondente
US7932390B2 (en) 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
MX2010001636A (es) 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
EP2596026B1 (en) 2010-07-23 2020-04-08 Trustees of Boston University Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
WO2014152661A1 (en) 2013-03-14 2014-09-25 Panoptica, Inc. Ocular formulations for drug-delivery to the posterior segment of the eye
RU2704810C2 (ru) * 2014-09-17 2019-10-31 Паноптика, Инк. Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза
WO2024140850A1 (zh) * 2022-12-28 2024-07-04 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂及其医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця

Also Published As

Publication number Publication date
EE200300247A (et) 2003-10-15
YU36403A (sh) 2006-08-17
CN1476439A (zh) 2004-02-18
US20020151573A1 (en) 2002-10-17
IS6788A (is) 2003-04-14
IL155371A0 (en) 2003-11-23
NO20032388L (no) 2003-07-18
CA2430065A1 (en) 2002-06-06
DOP2001000288A (es) 2002-12-15
SV2002000748A (es) 2002-12-02
GT200100237A (es) 2002-07-03
KR20030059275A (ko) 2003-07-07
UA74221C2 (uk) 2005-11-15
PL362079A1 (en) 2004-10-18
SI1337521T1 (sl) 2006-12-31
ECSP034628A (es) 2003-07-25
JP4971946B2 (ja) 2012-07-11
PT1337521E (pt) 2006-12-29
HK1059085A1 (en) 2004-06-18
MXPA03004714A (es) 2003-08-19
NZ525788A (en) 2004-11-26
DE60123461D1 (de) 2006-11-09
DK1337521T3 (da) 2007-01-29
UY27039A1 (es) 2002-07-31
AU2002214204B2 (en) 2007-05-24
SK5862003A3 (en) 2004-05-04
US6831091B2 (en) 2004-12-14
TNSN01167A1 (fr) 2005-11-10
TWI287542B (en) 2007-10-01
CA2430065C (en) 2008-05-20
CY1106240T1 (el) 2011-06-08
KR20050116401A (ko) 2005-12-12
BR0115621A (pt) 2003-09-02
JP2008056692A (ja) 2008-03-13
WO2002044158A1 (en) 2002-06-06
AR031512A1 (es) 2003-09-24
EP1337521B1 (en) 2006-09-27
PE20020591A1 (es) 2002-07-06
CR6963A (es) 2003-11-25
ZA200303341B (en) 2004-04-30
JP2004514714A (ja) 2004-05-20
ES2271086T3 (es) 2007-04-16
EP1337521A1 (en) 2003-08-27
PA8533801A1 (es) 2002-10-31
HRP20030408A2 (en) 2003-08-31
MA26960A1 (fr) 2004-12-20
CZ20031315A3 (cs) 2004-04-14
OA12532A (en) 2006-06-02
AP2001002358A0 (en) 2001-12-31
NO20032388D0 (no) 2003-05-27
ATE340786T1 (de) 2006-10-15
GEP20053652B (en) 2005-11-10
MY136686A (en) 2008-11-28
EA005859B1 (ru) 2005-06-30
EA200300424A1 (ru) 2003-10-30
BG107752A (bg) 2004-01-30
DE60123461T2 (de) 2007-02-15
AU1420402A (en) 2002-06-11
NO325187B1 (no) 2008-02-11
HN2001000268A (es) 2002-01-30
HUP0302553A3 (en) 2009-03-30
CN1231474C (zh) 2005-12-14

Similar Documents

Publication Publication Date Title
HUP0302553A2 (hu) Egy izotiazol-4-karbonsavamid sói és eljárás az előállításukra és ezek alkalmazására a túlzott mértékű sejtburjánzás visszaszorítására alkalmas gyógyszerkészítmények előállítására
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
ATE450533T1 (de) Carboxamidderivate
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
TW200619199A (en) 3-carbamoyl-2-pyridone derivatives
PA8529501A1 (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7."
TW200606164A (en) New compounds
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
WO2004100865A3 (en) New benzimidazole derivatives
NO20061575L (no) Fremgangsmate for fremstilling av renzapride og mellomprodukter derav
NO20040881L (no) Orale antidiabetes midler.
TW200800984A (en) New compounds
SE0102440D0 (sv) New compound
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
MXPA04005484A (es) Procedimiento de preparacion de derivados de equinocandina.
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
SE0102057D0 (sv) New Salts I
TW200510370A (en) Urea derivatives
SE9900190D0 (sv) New compounds
SE0102058D0 (sv) New Salts II
SE0301371D0 (sv) New Compounds
AR039177A1 (es) Derivados de morfolina, antagonistas de ccr3.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees